Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01506947
First received: December 28, 2011
Last updated: April 6, 2017
Last verified: April 2017
  Purpose
To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.

Condition Intervention Phase
Moderate to Severe Secondary Hyperparathyroidism
Stage 5 Chronic Kidney Diseases
Drug: Paricalcitol
Drug: Darbepoetin alfa
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients

Resource links provided by NLM:


Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • Mean Erythropoietin Dose Per Visit [ Time Frame: Baseline and Months 1, 2, 3, 4, 5 and 6 ]
    The requirement of erythropoietin (EPO) treatment to maintain serum hemoglobin levels between 10 to 11.5 g/dL during the study was assessed by analysis of the dose of darbepoetin alfa used at baseline and during each month of the study. The mean EPO dosage per injection for each study month is reported.


Secondary Outcome Measures:
  • Mean Scores of Short Form Health Survey 36 (SF-36) Questionnaire [ Time Frame: Baseline and Month 6 ]
    The Medical Outcome Study Short Form 36-Item Health Survey (SF-36) is a self-administered questionnaire that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains. The domains include physical (physical functioning, role limitations due to physical health (role-physical), general health perceptions and pain) and mental domains (energy/fatigue (vitality), social functioning, emotional well-being (mental health), and role limitations due to emotional problems (role emotional)). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

  • Mean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Mean Calcium Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Mean Phosphorus Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Mean Alkaline Phosphatase Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Vitamin B12 Levels [ Time Frame: Baseline and month 6 ]

    Vitamin B12 levels were categorized according to the following laboratory reference ranges:

    Low: < 200 pg/mL Normal: 200 - 950 pg/mL High: > 950 pg/mL


  • Folic Acid Levels [ Time Frame: Baseline and month 6 ]

    Folic acid levels were categorized according to the following laboratory reference ranges:

    Low: < 4.6 ng/mL Normal: 4.6 - 18.7 ng/mL High: > 18.7 ng/mL


  • Mean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Mean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6 [ Time Frame: Baseline and Month 6 ]
  • Number of Participants With Adverse Events [ Time Frame: From the time of study drug administration until 4 weeks after the discontinuation of the study drug; up to 7 months. ]

    Serious adverse events were any adverse events meeting any of the following criteria:

    • An event that resulted in the death of a participant;
    • An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken (life-threatening);
    • Resulted in an admission to the hospital for any length of time or prolonged hospital stay;
    • An anomaly detected at or after birth, or any anomaly that results in fetal loss;
    • An event that resulted in a condition that substantially interfered with the activities of daily living;
    • An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may have jeopardized the participant and may have required medical or surgical intervention to prevent any of the outcomes listed above.

    Adverse events were assessed by the investigator for possible relationship to study drug.



Enrollment: 65
Actual Study Start Date: May 10, 2012
Study Completion Date: April 7, 2016
Primary Completion Date: April 7, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paricalcitol

Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.

Participants may have also received routine darbepoetin alfa to treat anemia.

Drug: Paricalcitol

Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:

[Paricalcitol (µg) = iPTH (pg/mL) / 80]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.

Other Names:
  • ABT-358
  • Zemplar
Drug: Darbepoetin alfa
Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level < 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: A subject will only be included if all the following entry criteria are met:

  • Patients ≥ 18 years of age
  • Stage 5 chronic kidney disease (CKD) patients receiving hemodialysis and with moderate to severe secondary hyperparathyroidism (SHPT)
  • Patients with anemia due to renal insufficiency but who are iron replete:; Transferrin saturation (TSAT) > 20% and Ferritin levels > 200 ng/mL and requiring treatment with erythropoietin (EPO)
  • Patients with vitamin B levels > lower limit of normal (LLN) and folic acid levels > LLN
  • Patients treated only with intravenous calcitriol for at least 6 months
  • Patients with serum intact parathyroid hormone (iPTH) level > 500 pg/mL
  • Patients with calcium phosphate product (Ca × PO4) < 65 mg²/dL²
  • Patients willing to sign "written informed consents" before participating in any the study related activity.
  • Patients with phosphorus levels < 6.5 mg/dL and calcium levels < 11.2 mg/dL

Exclusion Criteria:

A subject will be excluded from the study if he/she meets any of the following criteria:

  • Patients who have known hypersensitivity and/or toxicity to vitamin D metabolites and/or to paricalcitol and/or to other product ingredients.
  • Patients who have participated in a clinical study within the last month.
  • Patients whose previous concomitant medication and laboratory data for 6 months prior to the baseline visit are not available.
  • Patients with known contraindication to selective Vitamin D receptor activators (VDRAs) according to the Summary of Product Characteristics (SmPC).
  • Pregnancy, breast-feeding or planning a pregnancy within next 6 months after enrollment. Sexually active female patients not accepting appropriate contraceptive methods during the course of the study will also be excluded.
  • Hypertensive and diabetic patients who are not on an optimal and steady medication regimen for more than 30 days.
  • Patients with microcytic (mean corpuscular volume [MCV] < 80 fL) and macrocytic (MCV > 100 fL) anemia at screening that may be caused by diseases such as for microcytic anemias - Iron Deficiency, Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zinc poisoning, Sideroblastic Anemia, macrocytic anemias -ethanol abuse, myelodysplastic syndromes, acute myeloid leukemias, reticulocytosis, drug induced anemia, liver disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01506947

Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
Study Director: Mahmut Gücük, MD AbbVie
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott)
ClinicalTrials.gov Identifier: NCT01506947     History of Changes
Other Study ID Numbers: W12-645
Study First Received: December 28, 2011
Results First Received: April 6, 2017
Last Updated: April 6, 2017

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):
Hemodialysis
Chronic kidney disease
Secondary hyperparathyroidism,

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Hyperparathyroidism
Hyperparathyroidism, Secondary
Renal Insufficiency
Urologic Diseases
Parathyroid Diseases
Endocrine System Diseases
Calcitriol
Ergocalciferols
Darbepoetin alfa
Epoetin Alfa
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Hematinics

ClinicalTrials.gov processed this record on May 25, 2017